Back to results

CompletedPhase 3

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

NCT00308139

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site 182

Encino, California, United States

+24 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2006-04
Enrollment: 303 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (25)

Research Site 182Encino, California, United States
Research Site 171La Jolla, California, United States
Research Site 518San Diego, California, United States
Research Site 024Walnut Creek, California, United States
Research SiteColorado Springs, Colorado, United States
Research Site 057Miami, Florida, United States
Research SiteChicago, Illinois, United States
Research Site 149Indianapolis, Indiana, United States
Research Site 099Lexington, Kentucky, United States
Research Site 017Detroit, Michigan, United States
Research Site 224Minneapolis, Minnesota, United States
Research Site 312St Louis, Missouri, United States
Research Site 023Butte, Montana, United States
Research Site 053Rochester, New York, United States
Research Site 002Durham, North Carolina, United States
Research Site 123Winston-Salem, North Carolina, United States
Research Site 405Cincinnati, Ohio, United States
Research Site 557Marion, Ohio, United States
Research Site 231Portland, Oregon, United States
Research Site 152Philadelphia, Pennsylvania, United States
Research Site 587Greer, South Carolina, United States
Research Site 015Dallas, Texas, United States
Research Site 009San Antonio, Texas, United States
Research Site 108Olympia, Washington, United States
Research SiteToronto, Ontario, Canada

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) — TrialFind